FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats[S]

• Published in: Journal of lipid research Vol. 51; no. 4; pp. 771 - 784
• Main Authors: Cipriani, Sabrina, Mencarelli, Andrea, Palladino, Giuseppe, Fiorucci, Stefano
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2010; American Society for Biochemistry and Molecular Biology; The American Society for Biochemistry and Molecular Biology; Elsevier
• Subjects: Animals; Chenodeoxycholic Acid - administration & dosage; Chenodeoxycholic Acid - analogs & derivatives; Chenodeoxycholic Acid - therapeutic use; Disease Models, Animal; Drug Therapy, Combination; Fatty Liver - blood; Fatty Liver - pathology; Fatty Liver - prevention & control; Gene Expression Regulation - drug effects; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - therapeutic use; Hypolipidemic Agents - administration & dosage; Hypolipidemic Agents - therapeutic use; Insulin Receptor Substrate Proteins - metabolism; Insulin Resistance; Lipid Metabolism - drug effects; Lipid Metabolism - genetics; Lipids - blood; Liver - drug effects; Liver - metabolism; Liver - pathology; Male; Muscle, Skeletal - drug effects; Muscle, Skeletal - metabolism; Obesity - blood; Obesity - complications; Phosphorylation - drug effects; Random Allocation; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear - agonists; Receptors, Cytoplasmic and Nuclear - genetics; Receptors, Cytoplasmic and Nuclear - metabolism; RNA, Messenger - metabolism; Rosiglitazone; Thiazolidinediones - administration & dosage; Thiazolidinediones - therapeutic use; Time Factors

The farnesoid X receptor (FXR) is a bile acid activated nuclear receptor. Zucker (fa/fa) rats, harboring a loss of function mutation of the leptin receptor, develop diabetes, insulin resistance, obesity, and liver steatosis. In this study, we investigated the effect of FXR activation by 6-ethyl-chen...